ALLMedicine™ Pituitary Tumors Center

Feb 25th, 2021 - Distinct genome-wide methylation patterns cluster pituitary neuroendocrine tumors (PitNETs) into molecular groups associated with specific clinicopathological features. Here we aim to identify, characterize and validate methylation signatures that...

Feb 12th, 2021 - P27, a cell cycle inhibitor, is also able to drive repression of Sox2 This interaction plays a crucial role during development of p27 -/- pituitary tumors because loss of one copy of Sox2 impairs tumorigenesis [H. Li et al., Cell Stem Cell 11, 845...

Feb 1st, 2021 - Pituitary neuroendocrine tumors (PitNETs) are the most common intracranial neoplasms. Although generally benign, they can show a clinically aggressive course, with local invasion, recurrences and resistance to medical treatment. No universally acc...

Jan 28th, 2021 - Pituitary tumors are discovered either incidentally by imaging studies (incidentalomas) or via evaluation of certain clinical symptoms (symptomatic tumors). In this study, we first surveyed patients with incidentalomas who underwent surgery. Cases...

Jan 25th, 2021 - Pituitary tumors are the second most common primary brain tumors. Functional tumors demonstrate increased PD-L1 expression, but expression of other checkpoint regulators has not been characterized. We sought to characterize the immune microenviron...

Sep 16th, 2016 - Nonfunctioning pituitary adenomas (NFPAs) are the most frequent pituitary tumors. To create evidence-based guidelines for the initial management of NFPAs. A multidisciplinary task force composed of physician volunteers and evidence-based medicine-...

Sep 16th, 2016 - Nonfunctioning pituitary adenomas (NFPAs) are the most frequent pituitary tumors. Visual symptoms from NFPAs are common and include visual field defects, loss of central vision, and motility problems resulting in diplopia. To create evidence-based...

Sep 16th, 2016 - Nonfunctioning pituitary adenomas (NFPAs) are the most frequent pituitary tumors. Due to the lack of hormonal hypersecretion, posttreatment follow-up evaluation of NFPAs is challenging. To create evidence-based guidelines in an attempt to formulat...

Feb 25th, 2021 - Distinct genome-wide methylation patterns cluster pituitary neuroendocrine tumors (PitNETs) into molecular groups associated with specific clinicopathological features. Here we aim to identify, characterize and validate methylation signatures that...

Feb 12th, 2021 - P27, a cell cycle inhibitor, is also able to drive repression of Sox2 This interaction plays a crucial role during development of p27 -/- pituitary tumors because loss of one copy of Sox2 impairs tumorigenesis [H. Li et al., Cell Stem Cell 11, 845...

Feb 1st, 2021 - Pituitary neuroendocrine tumors (PitNETs) are the most common intracranial neoplasms. Although generally benign, they can show a clinically aggressive course, with local invasion, recurrences and resistance to medical treatment. No universally acc...

Jan 28th, 2021 - Pituitary tumors are discovered either incidentally by imaging studies (incidentalomas) or via evaluation of certain clinical symptoms (symptomatic tumors). In this study, we first surveyed patients with incidentalomas who underwent surgery. Cases...

Jan 25th, 2021 - Pituitary tumors are the second most common primary brain tumors. Functional tumors demonstrate increased PD-L1 expression, but expression of other checkpoint regulators has not been characterized. We sought to characterize the immune microenviron...

Nov 7th, 2017 - Pituitary Tumors and Carcinomas European Society of Endocrinology Recommend all pituitary tumors undergo histopathologic analysis, which should include, at a minimum, immunodetection of pituitary hormones and Ki-67 proliferative index evaluation. ...

Apr 2nd, 2017 - ORLANDO – Temozolomide, an alkylating agent approved for glioblastoma, improved long-term survival in about half of patients who took it for aggressive pituitary tumors, a retrospective study has determined. The study, conducted by members of the.

May 26th, 2015 - Which of the following would you say has been the biggest advance in endocrinology over the past 20 years? Your Peers Chose: The discovery of leptin 0% Introduction of tyrosine kinase inhibitors (TKIs) in the management of advanced thyroid cancers...

Feb 20th, 2015 - ANSWER: D Critique The patient is most likely to have Zollinger-Ellison syndrome (ZES), a condition caused by a gastrinoma. In 25% of cases, ZES is associated with multiple endocrine neoplasia type 1 (MEN-1).

Mar 6th, 2012 - Interim results from an ongoing, registry-based phase IV surveillance study show that the medication pegvisomant is safe and effective in treating acromegaly, a disorder caused by pituitary tumors. Among 1,288 people treated for acromegaly with pe.